阻塞性睡眠呼吸暂停低通气综合征患者CYP3A4基因多态性的检测

目的探讨阻塞性睡眠呼吸暂停低通气综合征(OSAHS)CYP3A4基因的多态性,了解其对芬太尼类药物的敏感性及不同基因型的人群分布特征,指导临床个体化用药。方法对50例OSAHS患者进行CYP3A4基因的多态性检测,采静脉血,通过DNA抽提-PCR扩增-焦磷酸测序方法检测CYP3A4基因。结果野生纯合型型34例(68%),突变杂合型15例(30%),突变纯合型型1例(2%)。结论OSAHS患者中约2%为AA型,该型对芬太尼类药物极其敏感,术后有易发生窒息的风险,应高度警惕芬太尼类药物呼吸抑制的潜在风险。     

东莨菪碱-曲马多-芬太尼复合液用于剖宫产术后镇痛

目的观察静脉东莨菪碱配伍曲马多与芬太尼在剖宫产术后镇痛的临床效果及不良反应。方法ASAⅠ~Ⅱ级行剖宫产术病人60例,随机分为东莨菪碱组(S组)和氟哌利多组(D组),每组30例。S组,东莨菪碱0·3mg 曲马多500mg 芬太尼0·5mg;D组,氟哌利多2·5mg 曲马多500mg 芬太尼0·5mg。均以生理盐水配置100ml药袋,静脉给予负荷剂量4ml后连接镇痛泵进行病人自控镇痛(PCA)。术后24、48h行视觉模拟评分(VAS)和镇静评分,并对用药总量、PCA量及不良反应发生情况进行观察比较。结果两组VAS差异无显著意义。D组术后24h用药总量、PCA量和镇静评分均大于术后48h,D组术后24h镇静评分比S组高(P<0·05),不良反应发生率D组明显高于S组。结论东莨菪碱配伍曲马多及芬太尼应用于剖宫产术后镇痛安全有效,不良反应发生率明显低于氟哌利多。     

瑞芬太尼对老年患者麻醉诱导时血流动力学的影响

［摘要］目的观察瑞芬太尼全麻诱导对老年患者血流动力学的影响。方法60例ASAⅠ～Ⅱ级老年患者随机分成3组，F组、R1组和R2组，每组20例。F组静脉诱导用药：咪达唑仑0.05 mg·kg-1，芬太尼3 μg·kg-1，丙泊酚1 mg·kg-1，待入睡后注入维库溴铵0.1 mg·kg-1气管插管；R1组用瑞芬太尼1 μg·kg-1代替芬太尼；R2组用瑞芬太尼1.5 μg·kg-1代替芬太尼。观察诱导时血压、心率的变化，同时记录使用阿托品和麻黄碱情况。结果R2组最低血压（MAP1 ）、最高血压（MAP2）明显低于其他两组(P＜0.05＝； R2组 最低心率（HR1）、最高心率（HR2）明显低于F组(P＜0.05＝。结论瑞芬太尼可以用于老年患者的全麻诱导，但在诱导时要密切注意血流动力学变化。     

气管内硬膜外联合麻醉下的超前镇痛

目的研究气管内硬膜外联合麻醉下,硬膜外给药时间不同、全麻诱导药物不同对术后镇痛产生的影响。方法开腹行切除肝癌、胃癌的病人120例,随机分为A、B、C、D4组,每组30例。A组:在T8-9经硬膜外注入1%利多卡因和0.25%布比卡因混合液6～8ml,再经硬膜外注入含吗啡2mg、氟哌利多2.5mg的生理盐水10ml;全身麻醉诱导药物为芬太尼3μg·kg-1,异丙酚1～1.5mg·kg-1,琥珀胆碱2mg·kg-1。B组:诱导药物中不使用芬太尼,用利多卡因1～1.5mg·kg-1代替,术中也不使用芬太尼,其余条件同A组。C组:在T8-9行硬膜外穿刺,之后行全身麻醉诱导,诱导药物为芬太尼3μg·kg-1,异丙酚2～2.5mg·kg-1,琥珀胆碱2mg·kg-1,必要时可加芬太尼2～3μg·kg-1。切皮后90min,经硬膜外注入1%利多卡因和0.25%布比卡因6～8ml,再经硬膜外注入含吗啡2mg、氟哌利多2.5mg的生理盐水10ml。D组:诱导药物中不使用芬太尼,用利多卡因1～1.5mg·kg-1代替,术中也不使用芬太尼,其余条件同C组。分别于术毕后4、8、24、48h观测VAS、镇痛药消耗量、恶心、呕吐、骚痒等指标。结果A组的药物消耗量最少、镇痛效果最好;B组和C组次之;D组的药物消耗量最大,镇痛效果最差。结论硬膜外复合气管内麻醉时,硬膜外麻醉与芬太尼同时使用,术后镇痛效果最好。     

236例无痛人工流产术的疗效观察

目的:探讨异丙酚和芬太尼混合液静脉麻醉、笑气吸入麻醉及2%利多卡因宫颈局部浸润麻醉三种镇痛方法在人工流产手术中的疗效比较。方法:自2003年8月至2004年1月对236例妇科门诊早孕要求终止妊娠的妇女实施无痛人工流产术。随机分成3组。A组:异丙酚+芬太尼静脉麻醉(85例);B组:N2O(笑气)吸入麻醉(88例);C组:2%利多卡因宫颈局部浸润麻醉(63例),观察人流术中其镇痛效果并对疼痛进行分级。结果:A组85例100%可达到完全不痛(疼痛分级为0级);B组65.90%可达到完全不痛,Ⅰ级23.86%,Ⅱ级9.09%,Ⅲ级1.15%;C组0例可达到完全不痛,Ⅰ级63.49%,Ⅱ级30.16%,Ⅲ级6.35%。结论:受术者如无心肺疾患及人流禁忌证,无痛人工流产术应选择异丙酚+芬太尼静脉麻醉可达到完全无痛,痛苦最小。     

Respiratory muscle rigidity in a preterm infant after use of fentanyl during Caesarean section

Fentanyl is in many neonatal intensive care units the sedative of choice. One side-effect is, however, the possibility of muscle and/or chest wall rigidity. A pregnant woman with a critical pulmonary valve stenosis had a balloon dilatation at 26 weeks of gestation. She was put on propranolol, but went into a severe cardiac failure. In week 31, she developed pregnancy induced hypertension. Periodically absent diastolic flow in the umbilical cord was demonstrated. A Caesarean section was performed using fentanyl as analgesia. A boy weighing 1440 g, had a 1 min Apgar score of 3 without respiratory movements. Mask ventilation was tried, but chest wall expansion was not achieved despite using high pressures. He was intubated and positive pressure ventilation attempted, with the same result. Despite the use of high pressures up to 60–70 cm H₂O, no chest movement could be achieved. An intravenous line was established in order to give naloxone and pancuronium. Just before the drugs were given, chest wall movements were achieved and the heart rate normalized. Conclusion This is the first report on chest wall rigidity in a neonate after administration of fentanyl to the mother during Caesarean section. Received: 15 August 1997 and in revised form 30 January 1998 / Accepted 3 February 1998     

舒芬太尼对心脏瓣膜置换术患者麻醉诱导期血液动力学的影响

目的观察舒芬太尼对心脏瓣膜置换术患者麻醉诱导期血液动力学的影响。方法心脏瓣膜置换手术患者20例,随机分为舒芬太尼组(S组,n=10)和芬太尼组(F组,n=10)。全麻诱导:咪唑安定0.1～0.3mg/kg,维库溴铵0.1～0.2mg/kg。S组使用舒芬太尼1μg/kg,F组使用芬太尼10μg/kg。血液动力学监测:心电Ⅱ导联示波,有创动静脉测压,放置6腔Swan-Ganz导管,采用美国Baxter-2型连续心排血量多功能监测仪,测定心脏指数(CI)和肺毛细血管嵌压(PCWP)。观察心率(HR)、平均动脉压(MAP)、中心静脉压(CVP)、心脏指数(CI)和肺毛细血管嵌压(PCWP)。分别于麻醉诱导前(T1)、麻醉诱导后气管插管前(T2)、插管后1分钟(T3)、5分钟(T4)和10分钟(T5)记录观察指标。结果HR、MAP、CVP和PCWP两组变化趋势基本一致。麻醉诱导后及气管插管后部分时间S组HR和MAP低于F组(P<0.05或P<0.01),插管后S组CVP明显高于F组(P<0.05或P<0.01)。麻醉诱导或气管插管后,F组CI明显下降(P<0.05或P<0.01),S组均无明显变化。观察期间PCWP均无明显变化。结论舒芬太尼可安全的用于心脏瓣膜置换手术。     

脊麻药复合微量芬太尼对防治牵拉反应的探讨

目的 探讨脊麻药中复合微量芬太尼对牵拉反应的防治效果。方法 选择美国麻醉医师协会（american society of anesthesiologists，AsA）Ⅰ-Ⅱ级、足月、初产及单胎而需行剖宫产术的病人60例，随机分成2组，每组30例。2组病人的年龄、性剐、体重、局麻药用量、麻醉方法均无显著性差异，均选用腰硬联合麻醉（combined spinal—epidural anesthesia，CSEA）。A组：等比重0．5％罗哌卡因9-11mg＋芬太尼10μg。B组：等比重0．5％罗哌卡因9-11mg。观察术中牵拉反应和生命体征并记录，进行统计学处理。结果 2组间麻醉前、后相对应的MAP（平均动脉压）、HR（心率）、RR（呼吸频率）和SpO2（血氧饱和度）变化均无显著性差异（JP〉0．05），2组间新生儿Apgar评分均无显著性差异（P〉0．05），比较2组术中的牵拉反应，A组明显优于B组，有显著性差异（P〈0．05）结论 脊麻药中加入微量芬太尼对牵拉反应有良好的防治效果。     

Motor blockade associated with continuous epidural infusion after abdominal hysterectomy: a randomized controlled trial comparing 0.1% ropivacaine-plus-fentanyl versus 0.2% ropivacaine-alone

We compared rates of motor blockade, analgesia, adverse effects and patient satisfaction of 0.1% ropivacaine+fentanyl versus 0.2% ropivacaine-alone in a randomized, controlled trial. Fifty-four women who had undergone abdominal hysterectomy were randomly allocated into two groups to receive an epidural block at L_1–2 or L_2–3: group R received 0.2% ropivacaine-alone and group RF received 0.1% ropivacaine plus 2 μg fentanyl/ml, both at 8 ml/h. Rescue analgesia was provided via a morphine-loaded PCA device. Motor blockade (using a modified Bromage scale), pain intensity (visual analogue scale (VAS)), morphine consumption, level of sensory blockade and adverse effects, were measured at 4, 8 and 21 h after infusion. Patient satisfaction with pain management was assessed at the end of the study. The rates of motor blockade were not different at 8 h after infusion but at 21 h, group RF had significantly less motor blockade than group R. There were no differences in VAS, level of sensory blockade, adverse effects and patient satisfaction. Morphine consumption at each measurement was comparable but the total amount used by group RF was less than group R (12 mg versus 20 mg, P=0.049). Therefore, 0.1% ropivacaine with fentanyl 2 μg/ml appears to offer advantages over 0.2% ropivacaine-alone.     

新的高强度高选择性阿片μ受体激动剂[11C]-羟甲芬太尼的合成

羟甲芬太尼(I)是一个新的高强度高选择性阿片μ受体激动剂。本文用cis-A-N-[1-(2-羟基-2-苯乙基)-3-甲基-4-哌啶基]-苯胺(II)或cis-N-[1-(苯甲酰甲基)-3-甲基-4-哌啶基]-苯胺(III)作为前体合成了[¹¹C]-羟甲芬太尼,以便用正电子发射断层扫描(PET)来观察μ受体。通过水解cis-A-羟甲芬太尼(I)和cis-N-[1-(苯甲酰甲基)-3-甲基-4-哌啶]-N-苯基丙酰胺(cis-IV)的4-N-丙酰基分别获得II和III。溴乙烷的格氏试剂与回旋加速器产生的[¹¹C]-二氧化碳反应后继而直接加入邻苯二甲酸二酰氯和2,6-二叔丁基吡啶生成同位素标记中间体[¹¹C]-丙酰氯。[¹¹C]-丙酰氯与OH-前体(II)反应后再经HPLC分离纯化直接得[¹¹C]-羟甲芬太尼;[¹¹C]-丙酰氯与酮-前体(III)反应后,再用硼氢化钠甲醇溶液处理,然后进行HPLC分离纯化得[¹¹C]-羟甲芬太尼。两种方法均可获得ll.1～14.8GBq/μmol的特异性放射化学纯[¹¹C]-羟甲芬太尼。总共耗时为40～50min(EOB)。